Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade - Nouscom

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

By ef

Posted 09/27/2022

In Scientific publications

D’Alise AM et al., Nature Comms, 2019

Recent Posts

Nouscom Raises €67.5 million ($72 million) in Oversubscribed  Series C Financing Round
Dr. Morena D’Alise (VP of Immunology) is presenting at the SITC Annual Meeting 2023, San Diego November 1-3
Dr. Elisa Scarselli (Nouscom CSO) invited speaker at EHTG European Hereditary Tumour Group 2023, Vilnius September 28 – October 1st
Dr. Elisa Scarselli (CSO) invited speaker at Vaccines Europe 2023, Berlin September 13-15

error: Content is protected !!!